Biotech giant Vertex Pharmaceuticals, which made its name in the rare cystic fibrosis, is widening its aperture in hopes of treating a much more common ailment: chronic pain.
The company is wading into a risky, competitive race to develop drugs that work better than over-the-counter painkillers but don’t carry the deadly risks of opioid therapy.
About the Author Reprints
